Skip to content
Company Analysis

Organogenesis Holdings Inc. ORGO

A comprehensive view of key metrics, scores, and financial health for Organogenesis Holdings Inc.

Overview of Organogenesis Holdings Inc.

ORGO NCM
Healthcare Drug Manufacturers - Specialty & Generic Small Cap
Organogenesis Holdings Inc. (ORGO), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $2.64, about 240.2% undervalued vs fair value, -46.9% 1Y return, placing in the top 10% of its sector.
$2.64
-0.38%
As of March 13, 2026
Previous close • Vol 90d: 92.2%
Market Cap
$358.91M
Enterprise Value
$347.37M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Organogenesis Holdings Inc..

Top Beats

Quick Facts

Website https://organogenesis.com
HQ Canton, MA
Employees 854
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$8
$9
$10
Current: $2.64 +240% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$564.2M
17%%
Gross Profit
$366.3M
12.1%%
R&D Expense
$44.5M
-11.4%%
Operating Income (EBIT)
$49.3M
3999.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
-20.9%
Poor

Weak cash conversion - investigate working capital

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$36.8M
882.4% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
0/4
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Organogenesis Holdings Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
67
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
76
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing ORGO's balance between Growth (28.7%), Profitability (36.0%), and Safety (35.3%). Growth 29% Safety 35% Profitability 36%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

53th percentile vs peers
54
Key Signals
Rev Growth YoY 17.0% 68p Revenue CAGR 3Y 7.8% 52p TSR 64.7% 79p EPS Growth YoY -1.11 18p
Strengths
  • Interest Coverage Ratio in top 20% of peers (21.59, 95th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Net Profit Margin in top 20% of peers (10.1%, 82th percentile)
Risks
  • Eps Growth Yoy in bottom 20% of peers (-1.11)

Profitability

67th percentile vs peers
67
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

65th percentile vs peers
66
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Organogenesis Holdings Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$8.98
- - -
+240.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info